Results 161 to 170 of about 4,206 (188)

Nusinersen

Reactions Weekly, 2020
  +4 more sources

Nusinersen

Reactions Weekly, 2023
  +4 more sources

Nusinersen

Reactions Weekly, 2019
  +4 more sources

Nusinersen for the treatment of spinal muscular atrophy

Expert Review of Neurotherapeutics, 2017
Spinal muscular atrophy (SMA) is an autosomal recessive degenerative neuromuscular disorder characterized by loss of spinal motor neurons leading to muscle weakness. This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describes the exciting journey from early ASO clinical ...
openaire   +2 more sources

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study

Muscle and Nerve, 2021
Gyula Acsádi, Thomas O Crawford, Perry B Shieh   +2 more
exaly  

Children and young adults with spinal muscular atrophy treated with nusinersen

European Journal of Paediatric Neurology, 2021
Damjan Osredkar, Tita Butenko, Tanja Loboda   +2 more
exaly  

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy

Brain, 2023
Sabine Stein, Sibylle Vogt, Veronka Horber   +2 more
exaly  

Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen

Neuromuscular Disorders, 2021
Giorgia Coratti, Marika Pane, Simona Lucibello   +2 more
exaly  

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients

Journal of Cellular and Molecular Medicine, 2020
Irène Faravelli, Megi Meneri, Daniele Velardo   +2 more
exaly  

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients

European Journal of Neurology, 2022
Iddo Magen, Sharon Aharoni, Nancy Sarah Yacovzada   +2 more
exaly